目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key objectives of secondary research
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Company revenue analysis (Bottom-up approach)
2.2.1.2 MnM repository analysis
2.2.1.3 Primary interviews
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
3.1.1 PHARMACEUTICAL CONTRACT MANUFACTURERS
3.1.1.1 Capacity lock in for GLP-1 and biologics opportunities
3.1.1.2 Sterile fill-finish services
3.1.1.3 OSD differentiation and dual site sourcing
3.1.2 PHARMACEUTICAL COMPANIES
3.1.2.1 Own vs. outsourcing critical steps
3.1.2.2 Dual-source, multi-site supply resilience
3.1.3 STARTUPS AND INNOVATIVE BIOTECH FIRMS
3.1.3.1 Gene-to-IND platform
3.1.3.2 Clinical supply risk management

4 PREMIUM INSIGHTS
4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE AND COUNTRY, 2025
4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
4.4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
4.5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EMERGING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 GLP-1 capacity crunch
5.2.1.2 Increasing development and manufacturing of antibody drug conjugates
5.2.1.3 Loss of exclusivity of blockbuster biologics
5.2.1.4 Increasing complexity of injectable drug formats
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure on innovator drugs
5.2.2.2 Growing penetration of generics and biosimilars
5.2.2.3 Strict regulatory compliance
5.2.2.4 Risk in advanced therapies pipeline
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for cell and gene therapies
5.2.3.2 Growing inclination toward one-stop-shop model
5.2.3.3 Market expansion in emerging countries
5.2.3.4 Booming radiopharmaceutical and nuclear medicine segment
5.2.4 CHALLENGES
5.2.4.1 Global trade instability and insourcing
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICING ANALYSIS, BY SERVICE
5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION
5.4.3 COMPARISON OF CDMO PRICING MODELS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 MANUFACTURING SITE, EXPANSION, AND CAPEX TREND OF KEY CDMOS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Single-use bioprocessing systems
5.9.1.2 Continuous manufacturing
5.9.1.3 Advanced formulation technologies
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 High-performance liquid chromatography
5.9.2.2 Mass spectrometry
5.9.2.3 Next-generation sequencing
5.9.2.4 Automation and robotics
5.9.2.5 Process analytical technology
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 3D printing
5.9.3.2 Artificial intelligence and machine learning
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2025-2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENARIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 UNMET NEEDS OF END USERS
5.15.1 CAPACITY AND TIMELY ACCESS
5.15.2 COST EFFICIENCY AND FLEXIBILITY
5.15.3 END-TO-END INTEGRATED SERVICES
5.15.4 ADVANCED MODALITY EXPERTISE
5.15.5 QUALITY AND REGULATORY CONSISTENCY
5.16 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
5.17 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI/GEN AI
5.17.3 AI USE CASES
5.17.4 KEY COMPANIES IMPLEMENTING AI/GEN AI
5.18 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 US
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.4.3.1 India
5.18.5 IMPACT ON END-USE INDUSTRIES

6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
6.1 INTRODUCTION
6.2 PHARMACEUTICAL MANUFACTURING SERVICES
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
6.2.1.1 Rising cases of patent expiry to fuel market
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
6.2.2.1 Parenteral manufacturing services
6.2.2.1.1 Increasing demand for specialized manufacturing capabilities to support growth
6.2.2.2 Tablet manufacturing services
6.2.2.2.1 Growing domestic production capacity in emerging markets to boost market
6.2.2.3 Capsule manufacturing services
6.2.2.3.1 Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth
6.2.2.4 Oral liquid manufacturing services
6.2.2.4.1 Growing preference for oral liquids over powders to fuel market
6.2.2.5 Semi-solid manufacturing services
6.2.2.5.1 Rising prevalence of skin infections and burns to foster growth
6.2.2.6 Other FDF manufacturing services
6.3 DRUG DEVELOPMENT SERVICES
6.3.1 INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
6.4 BIOLOGICS MANUFACTURING SERVICES
6.4.1 BIOLOGICS API MANUFACTURING SERVICES
6.4.1.1 Rising investments in single-use production capacities to bolster growth
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
6.4.2.1 Growing demand for generic medicines and biologics to fuel market
6.5 PACKAGING & LABELING SERVICES
6.5.1 INCREASING COMPLEXITY AND STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR GROWTH
6.6 FILL-FINISH SERVICES
6.6.1 SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO BOOST MARKET
6.7 OTHER SERVICES

7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
7.1 INTRODUCTION
7.2 SMALL MOLECULES
7.2.1 HIGH-POTENCY SMALL MOLECULES
7.2.1.1 Increasing adoption of high-potency small molecules for treating oncology, rare diseases, and other diseases to aid growth
7.2.2 OLIGONUCLEOTIDE & SYNTHETIC PEPTIDES
7.2.2.1 Growing focus on next-gen therapies to drive market
7.2.3 RADIOPHARMACEUTICAL MOLECULES
7.2.3.1 Advances in isotope production, radiolabeling chemistry, and theranostic approaches to boost market
7.2.4 OTHER SMALL MOLECULES
7.3 LARGE MOLECULES
7.3.1 MONOCLONAL ANTIBODIES
7.3.1.1 Rising use of mAbs in managing cancer, autoimmune disorders, and osteoporosis to spur growth
7.3.2 CELL & GENE THERAPIES
7.3.2.1 Emerging treatments for previously untreatable genetic and rare diseases to boost market
7.3.3 ANTIBODY DRUG CONJUGATES
7.3.3.1 Growing need for precision medicines to fuel market
7.3.4 VACCINES
7.3.4.1 Growing threat of infectious disease outbreaks to drive market
7.3.5 THERAPEUTIC PEPTIDES & PROTEINS
7.3.5.1 Increasing research in genomics to support growth
7.3.6 OTHER LARGE MOLECULES

8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
8.1 INTRODUCTION
8.2 BIG PHARMACEUTICAL COMPANIES
8.2.1 PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO GROWTH
8.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
8.3.1 NEED TO SAVE IN-HOUSE DRUG MANUFACTURING COST TO FOSTER GROWTH
8.4 GENERIC PHARMACEUTICAL COMPANIES
8.4.1 FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
8.5 OTHER END USERS

9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 High clinical trial and drug discovery activities to foster growth
9.2.3 CANADA
9.2.3.1 Favorable government support and increased focus on R&D activities to sustain growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Free drug-pricing policy and high pharmaceutical investments to speed up growth
9.3.3 UK
9.3.3.1 Favorable R&D funding scenario to augment growth
9.3.4 FRANCE
9.3.4.1 Booming life science research and growing generics market to drive market
9.3.5 ITALY
9.3.5.1 Rising commercial drug development and increasing life science R&D to favor growth
9.3.6 SWITZERLAND
9.3.6.1 Rapid growth as global pharmaceutical manufacturing hub to drive market
9.3.7 POLAND
9.3.7.1 Universal health coverage and advanced government-supported medical infrastructure to encourage growth
9.3.8 SPAIN
9.3.8.1 Growing pharmaceutical R&D expenditure and increasing outsourcing of trial phases to boost market
9.3.9 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Made in China 2025 initiative and high government drug development investments to aid growth
9.4.3 JAPAN
9.4.3.1 High geriatric population and advanced pharmaceutical research to augment growth
9.4.4 SOUTH KOREA
9.4.4.1 Increased biotech investments and developed pharma sector to propel market
9.4.5 INDIA
9.4.5.1 Favorable industrial environment and lower labor costs to drive market
9.4.6 AUSTRALIA
9.4.6.1 Strategic geographical location and stringent regulatory environment to foster growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Rapid patient enrolment and increased focus on advanced clinical trials to expedite growth
9.5.3 MEXICO
9.5.3.1 Surge in pharmaceutical goods export to promote growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 Kingdom of Saudi Arabia (KSA)
9.6.2.1.1 Increasing healthcare expenditure to aid growth
9.6.2.2 UAE
9.6.2.2.1 Strategic government healthcare initiatives and broader economic diversification plans to drive market
9.6.2.3 Rest of GCC countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 RISING PREVALENCE OF CHRONIC DISEASES TO FACILITATE GROWTH
9.7.2 MACROECONOMIC OUTLOOK OF AFRICA

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE SHARE ANALYSIS, 2020-2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY VALUATION AND FINANCIAL METRICS
10.6 BRAND/SERVICE COMPARISON
10.6.1 THERMO FISHER SCIENTIFIC INC.
10.6.2 LONZA
10.6.3 WUXI BIOLOGICS AND WUXI APPTEC
10.6.4 CATALENT, INC.
10.6.5 SAMSUNG BIOLOGICS
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.7.1 STARS
10.7.2 EMERGING LEADERS
10.7.3 PERVASIVE PLAYERS
10.7.4 PARTICIPANTS
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.7.5.1 Company footprint
10.7.5.2 Region footprint
10.7.5.3 Service footprint
10.7.5.4 Molecule footprint
10.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
10.8.1 PROGRESSIVE COMPANIES
10.8.2 RESPONSIVE COMPANIES
10.8.3 DYNAMIC COMPANIES
10.8.4 STARTING BLOCKS
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.8.5.1 Detailed list of key startups/SMEs
10.8.5.2 Competitive benchmarking of key startups/SMEs
10.9 COMPETITIVE SCENARIO
10.9.1 SERVICE LAUNCHES
10.9.2 DEALS
10.9.3 EXPANSIONS

11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 THERMO FISHER SCIENTIFIC INC.
11.1.1.1 Business overview
11.1.1.2 Services offered
11.1.1.3 Recent developments
11.1.1.3.1 Service launches
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 LONZA
11.1.2.1 Business overview
11.1.2.2 Services offered
11.1.2.3 Recent developments
11.1.2.3.1 Deals
11.1.2.3.2 Expansions
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 CATALENT, INC.
11.1.3.1 Business overview
11.1.3.2 Services offered
11.1.3.3 Recent developments
11.1.3.3.1 Service launches
11.1.3.3.2 Deals
11.1.3.3.3 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 WUXI APPTEC
11.1.4.1 Business overview
11.1.4.2 Services offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses and competitive threats
11.1.5 WUXI BIOLOGICS
11.1.5.1 Business overview
11.1.5.2 Services offered
11.1.5.3 Recent developments
11.1.5.3.1 Service launches
11.1.5.3.2 Deals
11.1.5.3.3 Expansions
11.1.5.3.4 Other developments
11.1.6 SAMSUNG BIOLOGICS
11.1.6.1 Business overview
11.1.6.2 Services offered
11.1.6.3 Recent developments
11.1.6.3.1 Service launches
11.1.6.3.2 Deals
11.1.6.3.3 Expansions
11.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.1.7.1 Business overview
11.1.7.2 Services offered
11.1.7.3 Recent developments
11.1.7.3.1 Deals
11.1.7.3.2 Expansions
11.1.7.3.3 Other developments
11.1.8 EVONIK
11.1.8.1 Business overview
11.1.8.2 Services offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.9 FUJIFILM HOLDINGS CORPORATION
11.1.9.1 Business overview
11.1.9.2 Services offered
11.1.9.3 Recent developments
11.1.9.3.1 Deals
11.1.9.3.2 Expansions
11.1.10 ABBVIE INC.
11.1.10.1 Business overview
11.1.10.2 Services offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.10.3.2 Expansions
11.1.11 SIEGFRIED HOLDING AG
11.1.11.1 Business overview
11.1.11.2 Services offered
11.1.11.3 Recent developments
11.1.11.3.1 Deals
11.1.11.3.2 Expansions
11.1.12 MERCK KGAA
11.1.12.1 Business overview
11.1.12.2 Services offered
11.1.12.3 Recent developments
11.1.12.3.1 Deals
11.1.12.3.2 Expansions
11.1.13 ALMAC GROUP
11.1.13.1 Business overview
11.1.13.2 Services offered
11.1.13.3 Recent developments
11.1.13.3.1 Deals
11.1.13.3.2 Expansions
11.1.14 CHARLES RIVER LABORATORIES
11.1.14.1 Business overview
11.1.14.2 Services offered
11.1.14.3 Recent developments
11.1.14.3.1 Deals
11.1.14.3.2 Expansions
11.1.15 ASYMCHEM INC.
11.1.15.1 Business overview
11.1.15.2 Services offered
11.1.15.3 Recent developments
11.1.15.3.1 Deals
11.1.15.3.2 Expansions
11.1.16 VETTER
11.1.16.1 Business overview
11.1.16.2 Services offered
11.1.16.3 Recent developments
11.1.16.3.1 Service launches
11.1.16.3.2 Deals
11.1.16.3.3 Expansions
11.1.17 ALCAMI CORPORATION
11.1.17.1 Business overview
11.1.17.2 Services offered
11.1.17.3 Recent developments
11.1.17.3.1 Deals
11.1.17.3.2 Expansions
11.1.18 EUROFINS SCIENTIFIC
11.1.18.1 Business overview
11.1.18.2 Services offered
11.1.18.3 Recent developments
11.1.18.3.1 Expansions
11.2 OTHER PLAYERS
11.2.1 PIRAMAL PHARMA SOLUTIONS
11.2.2 SYNGENE INTERNATIONAL LIMITED
11.2.3 CAMBREX CORPORATION
11.2.4 JUBILANT PHARMANOVA LIMITED
11.2.5 YUHAN CORPORATION
11.2.6 PIERRE FABRE LABORATORIES
11.2.7 PFIZER CENTREONE
11.2.8 DELPHARM
11.2.9 FRONTAGE LABS
11.2.10 SHARP SERVICES, LLC
11.2.11 GRAND RIVER ASEPTIC MANUFACTURING
11.2.12 RECIPHARM AB
11.2.13 PCI PHARMA SERVICES
11.2.14 CURIA GLOBAL, INC.
11.2.15 SIMTRA BIOPHARMA SOLUTIONS
11.2.16 PORTON
11.2.17 MABPLEX INTERNATIONAL CO. LTD.
11.2.18 CELLARES

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS